Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

Here's why these two healthcare stocks scan as no-brainer buys right now.

The microcap biotech stock had its best day ever after the FDA granted its rare-disease drug a breakthrough designation. There are signs that some of the structural problems that have dogged the ...

Pfizer CEO Albert Bourla told Yahoo Finance that Pfizer has a "right to win" on the obesity drugs that have become a major ...

Pfizer said on Thursday it completed an acquisition worth up to $10 billion of biotech firm Metsera after winning shareholder ...

(Reuters) -Metsera shareholders on Thursday approved Pfizer’s takeover offer worth up to $10 billion, according to a preliminary vote count, securing a critical re-entry into the lucrative obesity ...

Pfizer on Thursday closed its up to $10 billion acquisition of Metsera after winning shareholder approval, gaining a foothold ...

After [losing out to Pfizer]( ...

Pfizer prevails 10B bidding for Metsera, securing a deal to expand its obesity drug portfolio with innovative weight-loss treatments.

Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what ...

Shares of Metsera fell over 15% in premarket trading on Monday, after the weight-loss drug developer accepted a sweetened ...

NEW YORK/LONDON (Reuters) -A bidding war over U.S. biotech Metsera was coming to a head on Thursday, with Danish drugmaker ...